Masimo Corp

Latest Results (07.08.2024):

Revenue Growth

Masimo Corp reported consolidated revenue of $548.9 million for the fourth quarter of 2023. This revenue was divided into $339.9 million from healthcare and $209.0 million from non-healthcare sectors. For the full year 2023, the company achieved consolidated revenue of $2,048.1 million, with healthcare contributing $1,275.5 million and non-healthcare $772.6 million.

Net Income

In the fourth quarter of 2023, Masimo Corp's GAAP net income was $34.0 million, translating to $0.63 per diluted share. On a non-GAAP basis, the net income was $66.9 million, or $1.25 per diluted share. For the full year 2023, GAAP net income stood at $81.5 million, or $1.51 per diluted share, while non-GAAP net income was $204.8 million, or $3.79 per diluted share.

Operating Income

Masimo Corp's consolidated GAAP operating income for the fourth quarter of 2023 was $44.1 million. On a non-GAAP basis, the operating income was $91.7 million. For the full year 2023, the company reported a GAAP operating income of $136.5 million, with non-GAAP operating income reaching $313.0 million.

Product Shipments

During the fourth quarter of 2023, Masimo Corp shipped 58,500 units of noninvasive technology boards and instruments, excluding handheld and fingertip pulse oximeters. For the entire year, the company shipped a total of 263,000 units of these products.

Future Outlook

Masimo Corp has provided guidance for the first quarter of 2024, estimating consolidated revenue between $476 million and $501 million. For the full year 2024, the company expects consolidated revenue to range from $2,045 million to $2,165 million, with healthcare revenue projected between $1,345 million and $1,385 million, and non-healthcare revenue between $700 million and $780 million.